Hemispherx Biopharma has met a major milestone, the commencement of sales of recently manufactured Ampligen in international programs. Hemispherx has also reinitiated its U.S.-based cost recovery program at the price increase recently approved by the FDA. The company says it has initiated an accelerated production plan with both its primary and secondary contract manufacturers in order to meet the anticipated future demand for Ampligen in both international programs as well as cost recovery programs.

“In the last quarter of 2016, we began manufacturing new lots of Ampligen. As I mentioned in our last stockholders call, we anticipated generating sales from our newly manufactured lots of Ampligen in the first quarter of 2017. Mission accomplished. We will continue to aggressively pursue this path while we seek FDA approval of Ampligen in the U.S.,” said Tom Equels, chief executive officer, Hemispherx.